摘要
目的:分析布地奈德福莫特罗联合噻托溴铵治疗慢性阻塞性肺疾病稳定期的临床效果。方法:选取2021年3月—2022年8月北京市朝阳区高碑店社区卫生服务中心全科门诊收治的60例慢性阻塞性肺疾病稳定期患者作为研究对象,采用随机数字表法分为对照组与观察组,各30例。对照组给予布地奈德福莫特罗治疗,观察组给予布地奈德福莫特罗联合噻托溴铵治疗。比较两组治疗效果。结果:治疗前,两组慢性阻塞性肺疾病患者自我评估测试问卷(CAT)、改良呼吸困难指数(mMRC)评分比较,差异无统计学意义(P>0.05);治疗后,两组CAT、mMRC评分低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。治疗前,两组呼吸困难问卷(SGRQ)评分与6分钟步行距离(6MWD)比较,差异无统计学意义(P>0.05);治疗后,两组SGRQ评分低于治疗前,且观察组低于对照组,两组6MWD大于治疗前,且观察组大于对照组,差异均有统计学意义(P<0.05)。两组用药后不良反应总发生率比较,差异无统计学意义(P=0.554)。结论:布地奈德福莫特罗联合噻托溴铵治疗慢性阻塞性肺疾病稳定期的临床效果显著,可改善患者症状,且未增加不良反应发生风险。
Objective:To analyze the clinical effect of budesonide formoterol combined with tiotropium bromide in the treatment of chronic obstructive pulmonary disease at stable stage.Methods:A total of 60 patients with chronic obstructive pulmonary disease at stable stage admitted to the General Practice Clinic of Beijing Chaoyang District Gaobeidian Community Health Service Center from March 2021 to August 2022 were selected as the study subjects.They were divided into control group and observation group according to random number table method,with 30 cases in each group.The control group was treated with budesonide formoterol,while the observation group was treated with budesonide formoterol combined with tiotropium bromide.The treatment effect was compared between two groups.Results:Before treatment,there was no significant difference in the scores of Chronic Obstructive Pulmonary Disease Assessment Test(CAT)and modified Medical Research Council dyspnoea scale(mMRC)between the two groups(P>0.05);After treatment,the CAT and mMRC scores in the two groups were lower than those before treatment,and the scores in the observation group were lower than those in the control group,with a statistically significant difference(P<0.05).Before treatment,there was no significant difference in the score of Saint George's Respiratory Questionnaire(SGRQ)and the 6-minute walk distance(6MWD)between the two groups(P>0.05);After treatment,the SGRQ score in the two groups was lower than that before treatment,and the score in the observation group was lower than that in the control group,while the 6MWD in the two groups was greater than that before treatment,and the 6MWD in the observation group was greater than that in the control group,and the difference was statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions after medication between the two groups(P=0.554).Conclusion:The combination of budesonide formoterol with tiotropium bromide in the treatment of chronic obstructive pulmonary disease at stable stage has significant clinical effects,and can improve the symptoms of patients,and will not increase the risk of adverse reactions.
作者
刘雪艳
林慧君
Liu Xueyan;Lin Huijun(Beijing Chaoyang District Gaobeidian Community Health Service Center,Beijing 100124,China)
出处
《中国社区医师》
2024年第6期59-61,共3页
Chinese Community Doctors
关键词
慢性阻塞性肺疾病
布地奈德福莫特罗
噻托溴铵
Chronic obstructive pulmonary disease
Budesonide formoterol
Tiotropium bromide
作者简介
通信作者:林慧君。
